AuthorisedTherapeutic use (Phase IV)Interventional

A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.

This research is a Phase 4 study focusing on adults with early rheumatoid arthritis. It's designed to compare how well different treatments work, including common medicines like hydroxychloroquine and methotrexate, alongside newer biologic drugs such as Cimzia and RoActemra. One main goal is to see if patients can achieve remission (when symptoms significantly improve or disappear) with these treatments. Another important part of the study looks at whether the doses of treatment can be safely reduced for patients who are responding well, which could help manage side effects and long-term costs. The study aims to provide more information on the best ways to treat rheumatoid arthritis from the beginning.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Karolinska Institutet

Enrolment target

705

Start

12 Nov 2024

Rheumatoid Arthritis

What is this study about?

This study is a bit like a careful comparison test for people who have been recently diagnosed with rheumatoid arthritis. Doctors want to understand the best ways to treat this condition from the start. They're looking at different types of medicines: some are the well-known, standard treatments, and others are newer, more targeted drugs called 'biologics'. The overall goal is to find out which treatments are most effective at making people feel better and reducing the impact of the disease. This is a 'Phase 4' study, meaning the treatments involved are already approved and available, but doctors are looking to learn more about how they work in real-world settings and in combination, especially for early-stage disease.

A key part of the research involves checking if patients can go into 'remission'. Remission means that your symptoms have significantly improved, or even disappeared, and the disease is much less active. The study will carefully measure if and when patients reach this stage with different treatments. They will also look at X-rays to see if the treatments are helping to protect joints from damage over time, which is very important in rheumatoid arthritis.

Another important aspect of this study is exploring 'de-escalation', which means carefully reducing the dose of medication once a patient is doing well. This is an exciting part of the research because if people can maintain their improvement on lower doses, it could mean fewer side effects and potentially make long-term treatment more manageable. So, in simpler terms, this study is trying to figure out which treatments work best for new rheumatoid arthritis patients, whether they can achieve remission, and if they can eventually reduce their medication while still staying well.

Key takeaways

This study compares standard and newer biologic treatments for early rheumatoid arthritis.
It aims to find out which treatments are best at achieving remission and protecting joints.
The study also investigates if medication doses can be safely reduced ('de-escalation') for those who respond well.
Participants will receive close medical monitoring and potentially new treatment strategies.
The research helps doctors understand the best long-term approaches for treating rheumatoid arthritis.
It is for adults aged 18 and over with early rheumatoid arthritis.

Who may be eligible?

To be considered for this study, you need to be an adult, 18 years old or older. The study is open to both men and women.

A very important factor is that you must have been recently diagnosed with rheumatoid arthritis. This study is specifically looking at early stages of the condition. Your doctors will check if your specific health situation matches the criteria needed for the study.

There might be other health conditions or medications you are taking that could affect whether you can join, but the doctors involved in the study will discuss all of these details with you thoroughly.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you recently been diagnosed with rheumatoid arthritis?
Are you willing to potentially try different types of approved treatments for your condition?
Are you able to attend regular clinic visits for examinations and tests?
Are you comfortable with the possibility of your medication dose being changed if you respond well?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you'll be assigned to one of several treatment groups. This decision is made randomly, like flipping a coin, to ensure fairness. You'll receive specific medications for your rheumatoid arthritis, as determined by your group. Some of these treatments will be standard care, while others might be newer biologic medications. Importantly, both you and your study doctor will know which treatment you are receiving, but the people who measure the results of your treatment will not know, to keep things unbiased.

You'll have regular appointments at the clinic for check-ups and assessments. These visits will involve blood tests, physical examinations, and possibly X-rays to monitor your condition and how well the treatment is working. The study is divided into two parts: in the first, doctors will look at how well the treatments work initially; in the second, for those who respond well, they will explore if the medication dose can be safely reduced. The total length of your participation will depend on the specific treatment plan and how you respond, but it will involve ongoing follow-up.

Potential risks and benefits

Taking part in this study could offer several potential benefits. You would receive close medical monitoring and access to treatments for your rheumatoid arthritis, possibly including novel biologic medications or new strategies for managing your condition, such as dose reduction. The information gained from your participation will also help others with rheumatoid arthritis in the future. However, there are potential risks, as with any medication. You might experience side effects from the study drugs, and not all treatments work for everyone. These will be fully explained before you agree to participate. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (4)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Iceland
—
Unverified
Denmark
—
Unverified
Norway
—
Unverified
Sweden

Common questions

What is rheumatoid arthritis?

Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. It's an autoimmune disease, meaning your body's immune system mistakenly attacks healthy cells.

What does 'remission' mean in this study?

In this study, 'remission' means that your rheumatoid arthritis symptoms have significantly improved or disappeared, and the disease is much less active, based on specific medical measurements.

What are 'biologic treatments'?

Biologic treatments are newer medicines made from living organisms. They target specific parts of the immune system that can cause inflammation in rheumatoid arthritis, often working differently from traditional drugs.

What is 'de-escalation'?

De-escalation means carefully and gradually reducing the dose of your medication once your rheumatoid arthritis is well-controlled and you are feeling much better. The aim is to find the lowest effective dose.

Will I know which treatment I'm receiving?

Yes, both you and your study doctor will know which treatment you are getting. However, the staff who measure and analyze your results will not know, which helps keep the study fair and unbiased.